Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 10

1.
Fig. 1

Fig. 1. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Model structure

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
2.
Fig. 7

Fig. 7. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Impact of prevention lag on optimal sending mix

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
3.
Fig. 3

Fig. 3. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Population growth in base case

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
4.
Fig. 5

Fig. 5. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Impact of discount rate on marginal cost-effectiveness

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
5.
Fig. 9

Fig. 9. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Impact of time horizon on optimal spending mix

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
6.
Fig. 10

Fig. 10. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Impact of research spending on population (not optimized)

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
7.
Fig. 6

Fig. 6. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Total QALYs and marginal cost-effectiveness as a function of spending mix

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
8.
Fig. 2

Fig. 2. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Illustrative impact of equations – death rate as a function of treatment spending

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
9.
Fig. 8

Fig. 8. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Impact of discount rate on optimal spending mix for alternative prevention lags

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.
10.
Fig. 4

Fig. 4. From: Tradeoffs in cardiovascular disease prevention, treatment, and research.

Marginal cost-effectiveness of additional treatment (prevention) spending as a function of prevention (treatment) spending level

George Miller, et al. Health Care Manag Sci. ;16(2):87-100.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk